The Data That Changes the Conversation On December 11, 2025, Lilly released topline results from TRIUMPH-4, its Phase III trial of retatrutide in patients with obesity and knee osteoarthritis
Consumers who have completed their own research and want to review product details can view the current Bioma GLP-1 Booster offer (official Bioma page)
As a glucagon-like peptide-1 (GLP-1) receptor agonist, Wegovy works by mimicking a naturally occurring hormone that regulates appetite and food intake
The result is selective fat tissue activation without any central nervous system effects on eating behavior
So, while you may be interested in taking a so-called natural GLP-1 supplement, youre unlikely to see a major impact on your weightat least, not nearly at the level that youd see if you took a GLP-1 receptor agonist medication
If future court rulings or FDA actions restrict compounded tirzepatide availability, patients may need to transition to brand-name products or alternative medications